From a heavy first model to a routine device
The first implanted defibrillators of around 1980 worked, but they were bulky and hard to place. The generator was typically implanted in the abdomen, wires were sewn to the outside of the heart through an opening in the chest, and the operation was major surgery. The origin of the idea is told in the article on Mirowski. This article covers the later development: how the device became smaller, easier to implant, more flexible and more widely used.
Why leads mattered
The lead is the insulated wire that carries signals from the heart to the device and the shock back to the heart. It sits in a hostile place, flexing with every beat, and it is arguably the most failure-prone part of any heart rhythm system. Defibrillator lead design had to solve several problems at once: it had to sense the heart rhythm accurately, deliver a strong shock, stay in place, resist breakage and avoid damaging tissue.
The first leads were patches. These were flexible electrodes placed against the surface of the heart through a surgical opening, with a second electrode somewhere else. The approach worked but required opening the chest, increased risk and recovery time, and made repeat operations difficult.
The move to transvenous leads
In the late 1980s, and more widely in the early 1990s, developers introduced leads that could be passed through a vein into the right side of the heart, in the same manner as pacemaker leads. A coil near the tip delivered the shock, and sometimes a second coil sat in a large vein above the heart. The combination meant that a defibrillator could be implanted without opening the chest, which lowered the risks of the operation and shortened recovery.
This change made the device appropriate for a larger group of patients, because the surgery was no longer so heavy. It also made it possible to use implant teams with training in pacemaker surgery rather than only cardiac surgeons.
Smaller generators and the pectoral pocket
As the leads changed, the generator shrank. Better capacitors, more efficient electronics and improved batteries reduced the size and weight of the pulse generator over about a decade. Eventually, the unit was small enough to be placed in a pocket under the skin below the collarbone, the same position used for pacemakers, instead of the abdomen. In some designs the metal case itself became part of the shock path, which simplified the lead system.
Improvements in the waveform helped too. Shocks of one polarity were replaced in most designs by biphasic shocks, which reverse direction during delivery and can defibrillate with less energy. A lower energy requirement allowed smaller capacitors and batteries. The wider story of pacemaker batteries runs in parallel, though ICDs need bursts of energy rather than steady low power. Small, reliable integrated circuits also allowed more sophisticated detection of rhythms and programmable therapies, including pacing to stop certain fast rhythms painlessly.
Devices also gained memory. They could record heart rhythm episodes, working like a miniature ECG machine that gave physicians data they could not previously see. Telemetry later allowed remote monitoring from home, an early step toward smart implants that report on themselves.
Trials and wider use
Technology was only half the story. A recurring question was who should get a defibrillator. The first patients were people who had survived cardiac arrest. Then, in the 1990s and 2000s, large randomized clinical trials with names such as MADIT, AVID, MADIT II and SCD-HeFT studied implanted defibrillators against drug treatment or other approaches in groups of patients at higher risk. Results generally supported the devices for specific groups, including some patients who had survived a dangerous rhythm and others with weakened heart function. Guidelines and insurance practices followed the evidence, and the number of implants rose substantially.
It is worth being careful with the details. Trial results apply to particular groups and time periods, benefits are not the same for everyone, and later analyses have refined the picture. Defibrillators can also deliver shocks that are unnecessary or distressing, and the decision to implant involves weighing benefits and risks.
Problems and lessons
The expansion of use revealed weaknesses. Some lead models proved prone to fracture or insulation wear and were recalled or monitored closely. Because a lead sits in the bloodstream, removing a damaged lead can be hard, particularly after years of scar tissue have grown around it. These problems pushed manufacturers and regulators toward better monitoring after approval and more detailed reporting of failures.
Later designs responded in different ways. One was the subcutaneous defibrillator, introduced in the 2010s, which places the lead under the skin outside the ribcage rather than inside the heart. It avoids some lead problems but cannot offer pacing in the same way. Another was the leadless pacemaker, which is a separate device but reflects the same concern about wires.
What this history shows
A medical invention often has two lives: the first demonstration, and the long engineering effort that makes it practical. Many of the improvements to the ICD were gradual and credited to teams rather than to individuals. This article is history only and not medical advice.